Eli Lilly-Incyte COVID drug doesn't meet primary endpoint

Thursday, 08. April 2021 13:01

Eli Lilly and Co. and Incyte Corp. announced on Thursday that the last trial phase of their COVID-19 drug baricitinib failed to meet statistical significance on the primary endpoint.

Baricitinib-treated patients were 2.7% less likely to progress to ventilation or die than those receiving standard of care, a difference that was not statistically significant, the companies said in a statement. However, the data showed a 38% reduction in mortality by day 28 in patients treated with baricitinib in addition to standard of care which includes corticosteroids and remdesivir.

"While COV-BARRIER did not hit the primary endpoint based on stages of disease progression, the data show that baricitinib meaningfully reduced the risk of mortality above and beyond the recommended standard of care, without additional safety risks," co-primary investigator Eugene Wesley Ely argued. Eli Lilly expects to publish the full data in the upcoming months.

Related Links: Eli Lilly & CompanyIncyte Corporation
Breaking the News / ND